- Previous Close
14.51 - Open
14.62 - Bid 14.54 x 300
- Ask 14.67 x 300
- Day's Range
14.38 - 15.04 - 52 Week Range
7.75 - 19.09 - Volume
620,347 - Avg. Volume
898,984 - Market Cap (intraday)
1.943B - Beta (5Y Monthly) 1.55
- PE Ratio (TTM)
-- - EPS (TTM)
-2.06 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.29
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
www.centessa.comRecent News: CNTA
View MorePerformance Overview: CNTA
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNTA
View MoreValuation Measures
Market Cap
1.94B
Enterprise Value
1.58B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.84
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.82%
Return on Equity (ttm)
-73.93%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-235.76M
Diluted EPS (ttm)
-2.06
Balance Sheet and Cash Flow
Total Cash (mrq)
482.18M
Total Debt/Equity (mrq)
29.34%
Levered Free Cash Flow (ttm)
-75.19M